These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33170819)

  • 1. Evaluating the potential benefits of the extravascular pool of factor IX.
    Lillicrap D
    Blood Coagul Fibrinolysis; 2021 Jan; 32(1):68-69. PubMed ID: 33170819
    [No Abstract]   [Full Text] [Related]  

  • 2. Extravascular factor IX pool fed by prophylaxis is a true hemostatic barrier against bleeding.
    Leuci A; Enjolras N; Marano M; Daniel M; Brevet M; Connes P; Dargaud Y
    J Thromb Haemost; 2024 Mar; 22(3):700-708. PubMed ID: 38072379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.
    Mansouritorghabeh H; Mohades ST
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):185-190. PubMed ID: 32611303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophilia B (Factor IX Deficiency).
    Sidonio RF; Malec L
    Hematol Oncol Clin North Am; 2021 Dec; 35(6):1143-1155. PubMed ID: 34607716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TFPI for hemophilia treatment.
    Peterson JA; Maroney SA; Mast AE
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical procedures in unsuspected hemophilia.
    Coy J; Bivins BA; Belin RP
    Arch Surg; 1974 Dec; 109(6):835-6. PubMed ID: 4421034
    [No Abstract]   [Full Text] [Related]  

  • 7. Small scale preparation and clinical use of factor IX-prothrombin complex.
    Barrowcliffe TW; Stableforth P; Dormandy KM
    Vox Sang; 1973 Nov; 25(5):426-41. PubMed ID: 4203167
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.
    Gui T; Reheman A; Ni H; Gross PL; Yin F; Monroe D; Monahan PE; Stafford DW
    J Thromb Haemost; 2009 Nov; 7(11):1843-51. PubMed ID: 19583826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V; Jouppila A; Lassila R
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Behavior of the coagulation factor IX following intravenous application of Tralysol in persons with Hematophilia B].
    Bierstedt P
    Klin Wochenschr; 1970 May; 48(10):632-4. PubMed ID: 5314171
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
    Kim HS; Kim JC; Lee YK; Kim JS; Park YS
    J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B.
    Gill JC; Roberts J; Li Y; Castaman G
    Haemophilia; 2019 May; 25(3):e219-e222. PubMed ID: 30866086
    [No Abstract]   [Full Text] [Related]  

  • 14. Massive hemorrhage into the iliopsoas muscle.
    Miyazaki K; Higashihara M
    Intern Med; 2005 Feb; 44(2):158-9. PubMed ID: 15750281
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Presence of inactive factor ix in variants of hemophilia, type B, and in carriers of hemophilia B].
    Elodi S
    Minerva Med; 1975 Jun; 66(42):2037-43. PubMed ID: 1138213
    [No Abstract]   [Full Text] [Related]  

  • 18. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Therapy Approaches for the Treatment of Hemophilia B.
    Soroka AB; Feoktistova SG; Mityaeva ON; Volchkov PY
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol.
    Young G; Ezban M; Clausen WHO; Negrier C; Oldenburg J; Shima M
    Haemophilia; 2017 Nov; 23(6):e528-e530. PubMed ID: 28922522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.